Neurocrine Biosciences, Inc.

Welsh biotech Draig Therapeutics has come out of stealth backed by an impressive line-up of healthcare investors and led by a highly experienced leadership team as it bids to become a major player in

Neurocrine Biosciences’ NBI-1117568 has shown significant improvement in symptoms and overall severity in adults with schizophrenia in new data presented from a Phase II dose-finding study, and the co

Industry leaders attending the Bank of America Global Healthcare Conference 13-14 May were pressed for early reaction to President Donald Trump’s executive order on US drug pricing, but with the confe

Executives still were struggling to understand the potential impact of President Trump’s executive order on US drug pricing for their companies’ top and bottom lines the day after its announcement. Tr